AZN STOCK ANALYSIS

AstraZeneca PLC — price, returns and risk statistics

AZNAstraZeneca PLC

🇬🇧 UK · LSE · Healthcare · Drug Manufacturers - General

Value itDuel

Price summary

Last Close

14,456.00 $

Jul 3, 26

Market Cap

301 B $

Q1 2026 (TTM)

52-Week Range

10,029.21 $15,542.00 $

Return and risk cards

Total Return

%+44.1

Trailing 1-year performance

Volatility

%25.3

Price fluctuation measure

Sharpe Ratio

-0.02

Risk/Return ratio

Sortino Ratio

-0.02

Downside risk/return

Distance to Peak

%-7.0

Difference from 52-week peak

Maximum Drawdown

-%15.4

Deepest 1-year decline

Seasonality

Seasonality Chart

Year 2023
Year 2024
Year 2025
Current Period 2026
3/3 positive months

Periodic Returns

1M

+9.4%

3M

-5.6%

6M

+7.5%

YTD

+5.9%

1Y

+44.1%

3Y

+45.1%

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date
AZN+5.9%Gold-3.2%Silver-10.4%FTSE 100+7.5%

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The FTSE 100 index is measured in its own currency.

Monthly positivity

Monthly Avg Positive/Negative Close

Positive Count
Negative Count
Average Positive %
Average Negative %

Frequently Asked Questions

What is the current AstraZeneca PLC (AZN) stock price?

AZN last closed at 14,456.00 $ (Jul 3, 26). Price data is refreshed after every trading day.

What is the P/E ratio of AZN?

AstraZeneca PLC trades at a trailing-twelve-month P/E of 28.79. See the comparison tables on the Peers tab for the industry context.

What is the market capitalization of AstraZeneca PLC?

AstraZeneca PLC (AZN) has a market capitalization of approximately 301 B $ as of the latest reported period.

Who are the main competitors of AZN?

Key peers of AstraZeneca PLC include Organon & Co, Grifols S.A., AstraZeneca PLC, Biogen Inc, Bayer AG NA. A detailed metric comparison is available on the Peers tab.

Go deeper on AZN

Data on this page refreshes once per day. Price data as of Jul 3, 26. This content is for informational purposes only and is not investment advice.